<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28562" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rho(D) Immune Globulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yoham</surname>
            <given-names>Athina L.</given-names>
          </name>
          <aff>University of Miami</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Casadesus</surname>
            <given-names>Damian</given-names>
          </name>
          <aff>Jackson Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Athina Yoham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Damian Casadesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28562.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rho(D) immune globulin (RhIG) is a medication used to manage and treat Rh-negative pregnancies and immune thrombocytopenic purpura. It is in the immune globulin biological class of drugs. This activity reviews the indications, action, and contraindications for RhIG as a valuable agent in managing RhIG in preventing hemolytic disease of the newborn and immune thrombocytopenic purpura and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring, relevant interactions) pertinent for healthcare team members in managing patients with Rh-negative pregnancies, immune thrombocytopenic purpura, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of Rho(D) immune globulin.</p></list-item><list-item><p>Describe the adverse effects and contraindications of Rho(D) immune globulin.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of Rho(D) immune globulin.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when dosing and monitoring warfarin to improve patient outcomes for those receiving Rho(D) immune globulin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28562">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28562.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rho(D) immune globulin (anti-D immune globulin or RhIG) is a commercial biological antibody derived from human plasma that targets red blood cells (RBCs) positive for the Rh(D) antigen (also referred to as the D antigen). When a blood type is described as positive (A+, B+, AB+, O+), the individual has RBCs that are positive for the D antigen and are thus Rh-positive.</p>
        <p>RhIG is known for its use&#x000a0;in preventing hemolytic disease of the fetus and neonate, which is the result of transplacental passage of anti-D antibodies due to previous exposure to an incompatible Rh blood type of either a previous pregnancy or received blood products. If the Rh-negative mother forms anti-D antibodies, this is known as Rhesus (Rh) isoimmunization. These maternally-derived anti-D antibodies may cross the placenta and target Rh-positive fetal RBCs for destruction resulting in hemolysis. This hemolytic disease may have devastating effects on the fetus, depending on the severity of the immune response. &#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
        <p>Several trademark names for RhIG products exist in the United States. Although Rho(D) immune globulin is a specific brand name, it is the common parlance used to refer to all RhIG products. Careful examination of the product insert is necessary to establish the associated indications and other unique characteristics.&#x000a0;</p>
        <p>Indications for RhIG vary by manufacturer. An&#x000a0;FDA-approved RhIG product exists for each of the following indications:</p>
        <list list-type="order">
          <list-item>
            <p>Immune thrombocytopenic purpura (ITP)
<list list-type="bullet"><list-item><p>Rh(D)-positive, non-splenectomized
<list list-type="bullet"><list-item><p>Chronic ITP in children and adults</p></list-item><list-item><p>Acute ITP in children</p></list-item><list-item><p>Improving platelet counts secondary to HIV infection</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Rh isoimmunization suppression&#x000a0;
<list list-type="bullet"><list-item><p>Rh(D)-negative, non-sensitized patient&#x000a0;with Rh-incompatible fetus
<list list-type="bullet"><list-item><p>Prophylaxis in the following clinical situations:&#x000a0;</p></list-item><list-item><p>Routine antepartum and postpartum mothers</p></list-item><list-item><p>Obstetric complications (ectopic pregnancy, threatened abortion, fetal demise in second or third trimesters)</p></list-item><list-item><p>Spontaneous or induced abortions</p></list-item><list-item><p>Following invasive obstetric procedures <xref ref-type="bibr" rid="article-28562.r1">[1]</xref></p></list-item><list-item><p>Abdominal trauma involving fetal-maternal hemorrhage&#x000a0;</p></list-item></list>
</p></list-item><list-item><p>Incompatible transfusions of Rh(D)-positive RBCs in Rh(D)-negative individuals <xref ref-type="bibr" rid="article-28562.r2">[2]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Possible <bold>non-FDA-approved&#x000a0;</bold>uses of RhIG:</p>
        <list list-type="order">
          <list-item>
            <p>Anti-D alloimmunization prophylaxis after platelet transfusion of Rh-positive individuals to&#x000a0;Rh-negative patients with acute leukemia due to possible RBC residual in platelet concentrates.<xref ref-type="bibr" rid="article-28562.r3">[3]</xref>&#x000a0;[Level 3]</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28562.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action for patients receiving RhIG in&#x000a0;immune thrombocytopenic purpura treatment is not entirely understood. Prevention of Rh isoimmunization appears to be an immunologic blockade of Fc receptors (RcR) within the reticuloendothelial system (RES); other immunomodulatory effects are also possible. Intravenous infusion of anti-D into an Rh-positive recipient leads to antibody coating of the circulating erythrocytes, which are eventually cleared primarily by the spleen. Clearance of sensitized erythrocytes by the RES results in increased platelet counts and reduced bleeding.<xref ref-type="bibr" rid="article-28562.r4">[4]</xref><xref ref-type="bibr" rid="article-28562.r5">[5]</xref></p>
        <p>The mechanism by which RhIG prevents isoimmunization is not completely understood but is likely to suppress the immune response and antibody formation in Rh-incompatible individuals (Rh-negative exposed to Rh-positive RBCs). If administration occurs within 72 hours of full-term delivery, the incidence decreases from 12%&#x000a0;or 13% to 1% or&#x000a0;2%.&#x000a0;The chances of isoimmunization drop to less than 1% with the administration schedule at 28 weeks gestation and within 72-hours postpartum.<xref ref-type="bibr" rid="article-28562.r2">[2]</xref><xref ref-type="bibr" rid="article-28562.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28562.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration of RhIG for prevention of Rh isoimmunization is achieved by either intramuscular (IM) or intravenous (IV) injection, depending on the indication and manufacturer recommendations. During pregnancy, a single dose should be given prophylactically at weeks 26&#x000a0;to 28 and again within 72 hours of delivery of an Rh-positive infant.</p>
        <p>For any known or suspected maternal exposure to Rh-positive RBCs or any incompatible Rh-positive blood product received, RhIG should be administered within 72 hours and dosed accordingly to the amount of RBC exposure per manufacturer guidelines. In pregnant women, RhIG should be administered every 12 weeks from the first injection to maintain a sufficient quantity of passively acquired anti-D antibodies. &#x000a0;</p>
        <p>Administration of RhIG for immune thrombocytopenic purpura is via IV infusion only.<xref ref-type="bibr" rid="article-28562.r7">[7]</xref>&#x000a0;There is a risk of complement system activation when IM-only preparations are given&#x000a0;intravenously and should always be avoided in patients with immune thrombocytopenic purpura. Peak serum levels are achieved faster with IV administration; however, the half-life is approximately the same (24 days) for IV and IM administration. Dosages are expressed in micrograms or international units (IUs). The conversion scale is 1 microgram = 5 IUs. The presence of RhIG can persist for months after administration and varies by the individual immune response.<xref ref-type="bibr" rid="article-28562.r8">[8]</xref></p>
      </sec>
      <sec id="article-28562.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects include<xref ref-type="bibr" rid="article-28562.r9">[9]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chills</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Asthenia</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Infection</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Vasodilation</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Shivering</p>
          </list-item>
          <list-item>
            <p>Diaphoresis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pallor</p>
          </list-item>
          <list-item>
            <p>Decreased hemoglobin in patients with immune thrombocytopenic purpura</p>
          </list-item>
          <list-item>
            <p>Increased lactate dehydrogenase&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Decreased haptoglobins</p>
          </list-item>
          <list-item>
            <p>Increased serum bilirubin</p>
          </list-item>
          <list-item>
            <p>Abdominal and back pain</p>
          </list-item>
          <list-item>
            <p>Antibody development (positive anti-C antibody test)</p>
          </list-item>
          <list-item>
            <p>Injection site reaction - erythema, discomfort, mild pain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hyperkinetic muscle activity&#x000a0;</p>
          </list-item>
        </list>
        <p>The most serious adverse interactions include<xref ref-type="bibr" rid="article-28562.r10">[10]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Disseminated intravascular coagulation</p>
          </list-item>
          <list-item>
            <p>Intravascular hemolysis (immune thrombocytopenic purpura patients)</p>
          </list-item>
          <list-item>
            <p>Acute renal insufficiency</p>
          </list-item>
          <list-item>
            <p>Clinically compromising anemia</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28562.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The FDA-labeled contraindications for RhIG vary by manufacturer but include the following:</p>
        <list list-type="order">
          <list-item>
            <p>A hemolytic reaction may result if given to Rh-positive patients; RhIG should be avoided in these individuals.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with a history of severe hypersensitivity or anaphylaxis to any human immune globulin product.</p>
          </list-item>
          <list-item>
            <p>Patients with preexisting hemolysis, autoimmune hemolytic anemia, or high risk for hemolysis.</p>
          </list-item>
          <list-item>
            <p>RhIG products may contain a small quantity of IgA and should be avoided in IgA deficient&#x000a0;individuals with antibodies against IgA.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28562.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>According to&#x000a0;published monitoring parameters on Rh(D) immune globulin, if indicated for the alloimmunization prophylaxis, after administration, patients should be monitored for at least 20 minutes to watch for any signs of systemic reactions. &#x000a0;</p>
        <p>If using RhIG to treat immune thrombocytopenic purpura, the black-box warning recommends closely monitoring patients for at least 8 hours to rule out any evidence of intravascular hemolysis. While most patients will be asymptomatic, signs and symptoms to be mindful of in a minority of patients include fever, back pain, shaking chills, and discolored urine or hematuria, which may indicate hemolysis.<xref ref-type="bibr" rid="article-28562.r10">[10]</xref></p>
        <p>Recommended labs for monitoring before treatment initiation include complete blood count (baseline anemia assessment and degree of hemolysis), differential and PBS review (evidence of hemolysis, infection), direct antiglobulin&#x000a0;test and antibody screen, reticulocyte count, urinalysis, serum creatinine, and BUN.<xref ref-type="bibr" rid="article-28562.r10">[10]</xref></p>
        <p>Recommended labs&#x000a0;to monitor following treatment include complete blood count&#x000a0;(1&#x000a0;to 3 days after infusion if first administration), urinalysis 1&#x000a0;to 2 hours after treatment (dipstick only, unless positive for blood), serum creatinine (only if posttreatment hemoglobin decreased greater than 1 g/dL), and BUN (only if posttreatment hemoglobin decreased greater than 1 g/dL).<xref ref-type="bibr" rid="article-28562.r10">[10]</xref></p>
        <p>If intravascular hemolysis is suspected, monitor plasma hemoglobin, LDH, haptoglobin, and plasma bilirubin (direct and indirect).&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-28562.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe and life-threatening toxicities are rare with RhIG treatments. In the event of an overdose in immune thrombocytopenic purpura, patients should&#x000a0;be closely monitored&#x000a0;to check that the hemoglobin doesn't decrease by&#x000a0;more than 1.2 g/dL.<xref ref-type="bibr" rid="article-28562.r11">[11]</xref></p>
        <p>In the suppression of Rh isoimmunization, hemolytic reactions can occur in the case of incompatible blood transfusions after very large doses of RhIG.</p>
        <p>Patients should be monitored closely for signs and symptoms of hemolysis with the initiation of supportive treatment at the start of symptoms.</p>
      </sec>
      <sec id="article-28562.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Several&#x000a0;RhIG products are&#x000a0;currently&#x000a0;available in the United States.&#x000a0;Although there are&#x000a0;multiple&#x000a0;brand names, they all have similar clinical indications and dosing but differ significantly in specific attributes. Pharmacists can play an essential role in ensuring the safe administration of these products by guiding clinicians on the use and timing of RhIG therapy. This is&#x000a0;one example of the kind of interprofessional activity that must accompany RhIG therapy, with clinicians, mid-level practitioners, specialists, nurses, and pharmacists working and communicating collaboratively to achieve optimal patient outcomes while minimizing adverse effects. [Level 5]</p>
        <p>The recommendation is to delay live&#x000a0;vaccine&#x000a0;administration&#x000a0;until at least 12 weeks after the last dose of RhIG.&#x000a0;However, according to CDC guidelines, postpartum vaccination of rubella-susceptible women with rubella or MMR vaccine should not&#x000a0;be delayed&#x000a0;during the&#x000a0;last trimester or delivery. It should&#x000a0;be serologically tested&#x000a0;6&#x000a0;to 8 weeks post-vaccination to ensure that seroconversion has occurred.</p>
        <p>If RhIG&#x000a0;is inadvertently omitted&#x000a0;after delivery, it should&#x000a0;be given&#x000a0;as soon as possible within the first 72 hours.&#x000a0;Partial protection can&#x000a0;be achieved&#x000a0;when administered with 13 days of birth and may provide some benefit as much as 28 days after delivery; the longer the delay, the less protective.<xref ref-type="bibr" rid="article-28562.r12">[12]</xref><xref ref-type="bibr" rid="article-28562.r13">[13]</xref>&#x000a0;[Level 2]&#x000a0;[Level&#x000a0;3]</p>
      </sec>
      <sec id="article-28562.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28562">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28562/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28562">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28562.s11">
        <title>References</title>
        <ref id="article-28562.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Makar</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Detection of fetomaternal hemorrhage.</article-title>
            <source>Am J Hematol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-23</page-range>
            <pub-id pub-id-type="pmid">22231030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The prevention of rh-immunization.</article-title>
            <source>Can Fam Physician</source>
            <year>1977</year>
            <month>Dec</month>
            <volume>23</volume>
            <fpage>60</fpage>
            <page-range>60-8</page-range>
            <pub-id pub-id-type="pmid">20469282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villalba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freiria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fuentes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodriguez-Veiga</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Carpio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solves</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2018</year>
            <month>May</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>162</fpage>
            <page-range>162-166</page-range>
            <pub-id pub-id-type="pmid">29928170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ware</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Anti-D: mechanisms of action.</article-title>
            <source>Semin Hematol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1 Suppl 1</issue>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">9523745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crow</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?</article-title>
            <source>Transfus Med Rev</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-16</page-range>
            <pub-id pub-id-type="pmid">18353251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowther</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Anti-D administration after childbirth for preventing Rhesus alloimmunisation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2000</year>
            <volume>1997</volume>
            <issue>2</issue>
            <fpage>CD000021</fpage>
            <pub-id pub-id-type="pmid">10796089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Costumbrado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghassemzadeh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Rh Incompatibility</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">29083656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Graziano</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kimberly</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aledort</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.</article-title>
            <source>Blood</source>
            <year>1991</year>
            <month>May</month>
            <day>01</day>
            <volume>77</volume>
            <issue>9</issue>
            <fpage>1884</fpage>
            <page-range>1884-93</page-range>
            <pub-id pub-id-type="pmid">1850307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malinoski</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Woloski</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of WinRho anti-D.</article-title>
            <source>Semin Hematol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1 Suppl 1</issue>
            <fpage>9</fpage>
            <page-range>9-13</page-range>
            <pub-id pub-id-type="pmid">9523744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Despotovic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>McCrae</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).</article-title>
            <source>Transfusion</source>
            <year>2012</year>
            <month>May</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>1126</fpage>
            <page-range>1126-36; quiz 1125</page-range>
            <pub-id pub-id-type="pmid">21981825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.</article-title>
            <source>Biologics</source>
            <year>2009</year>
            <volume>3</volume>
            <fpage>57</fpage>
            <page-range>57-62</page-range>
            <pub-id pub-id-type="pmid">19707396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mollison</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Effect on primary Rh immunization of delayed administration of anti-Rh.</article-title>
            <source>Immunology</source>
            <year>1975</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>349</fpage>
            <page-range>349-57</page-range>
            <pub-id pub-id-type="pmid">804437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28562.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung Kee Fung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eason</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De La Ronde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Farine</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keenan-Lindsay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leduc</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Aerde</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D&#x000e9;silets</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>DC</given-names>
              </name>
              <collab>Maternal-Fetal Medicine Committee, Genetics Committee</collab>
            </person-group>
            <article-title>Prevention of Rh alloimmunization.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>765</fpage>
            <page-range>765-73</page-range>
            <pub-id pub-id-type="pmid">12970812</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
